SuperworthCaris Life Sciences CAI
- Market cap
- $9B
- PE
- 86.5×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 9.1×
- EV/EBIT
- 56.4×
- Revenue, 12 months
- $989.6M
- +85% on a year ago
- Net margin
- 10.6%
- Free cash flow yield
- 1.4%
Caris Life Sciences trades at 86.5× trailing earnings. Revenue was $989.6M over the last twelve months, up 85% on a year earlier with a 11% net margin.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| $80.7M | $100M | $101.6M | $129.9M | $120.9M+50% | $181.4M+81% | $216.8M+113% | $292.9M+125% | $216.2M+79% | $263.7M+45% | |
| Cost of revenue | $54.6M | $62.5M | $57.2M | $59.2M | $63.9M+17% | $67.7M+8% | $69.3M+21% | $72M+22% | $74.8M+17% | $84.1M+24% |
| Gross profit | $26.1M | $37.6M | $44.4M | $70.7M | $57.1M+119% | $113.7M+203% | $147.5M+232% | $220.9M+213% | $141.3M+148% | $179.6M+58% |
| R&D | $34.4M | $24.8M | $27.6M | $27.1M | $23.1M−33% | $25M+1% | $21.6M−22% | $31.8M+18% | $31.3M+36% | $32.4M+29% |
| SG&A | $84M | $79.8M | $77.6M | $80.6M | $91.9M+10% | $106.6M+34% | $93.2M+20% | $100.7M+25% | $104.8M+14% | $120.3M+13% |
| −$92.2M | −$67M | −$60.8M | −$37M | −$58M−37% | −$18M−73% | $32.6M | $88.4M | $5.3M | $26.9M | |
| Interest expense | $9.3M | $13.7M | $13.8M | $13.3M | $12.8M+38% | $19.2M+41% | $13.5M−2% | $11.4M−14% | $12.8M+0% | $9.2M−52% |
| Pre-tax income | −$111M | −$66.2M | −$67.7M | −$36.9M | −$102.6M−8% | −$71.8M+9% | $24.3M | $82M | −$644K−99% | −$614K−99% |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$134K | $23K | |
| Net income | −$111M | −$66.2M | −$67.7M | −$36.9M | −$102.6M−8% | −$71.8M+9% | $24.3M | $82M | −$510K−100% | −$637K−99% |
| −$3.80 | −$2.54 | −$2.59 | −$1.74 | −$3.57−6% | −$7.97+214% | $0.08 | $0.29 | $0.00 | $0.00 | |
| 35.3M | 35.4M | 35.6M | 35.7M | 35.6M+1% | 64.9M+84% | 297.2M+734% | 282.2M+692% | 282.6M+693% | 282.9M+336% |
Revenue: Q1 FY24: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY24: 6 months less the 3 months printed beside them. 9 periods, Q2 FY24 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY24: 6 months less the 3 months printed beside them.
SG&A: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Operating income: Q1 FY24: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY24: 6 months less the 3 months printed beside them.
Income tax: Q1 FY24 and Q1 FY25: 6 months less the 3 months printed beside them.
Net income: Q1 FY24: 6 months less the 3 months printed beside them.
EPS, diluted: 4 periods, Q1 FY24 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY24: share-days: the 6-month average less the second quarter's. Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest Caris Life Sciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CAICaris Life Sciences | $9B | 86.5× | 73.7× | n/m | 9.1× | +85% | 10.6% |
| BIOBio-Rad Laboratories | $9.9B | 44.8× | 30.8× | n/m | 3.8× | +1% | 8.6% |
| LNTHLantheus | $6.5B | 24.2× | 24.0× | n/m | 4.2× | +2% | 17.7% |
| BLLNBillionToOne | $5.1B | 166× | 151× | n/m | 12.8× | +90% | 9.5% |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | n/m | 6.1× | +4% | 8.2% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | n/m | 6.9× | +17% | 20.4% |
| CDNACareDx | $3.6B | 33.4× | 19.1× | n/m | 7.8× | +34% | 24.2% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| Peer median | $13.8B | 35.9× | 32.6× | 25.6× | 6.4× | +8% | 13.6% |
Investors who own it
Investors we follow who held Caris Life Sciences at the end of Jun 30, 2026, from their 13F filings.
- Stanley DruckenmillerDuquesne Family Office0.8% of portfolio
- Philippe LaffontCoatue Management0.4% of portfolio
More on Caris Life Sciences
Each number over time
Where it ranks
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .